Short regimen of rituximab plus lenalidomide in follicular lymphoma patients in need of first-line therapy
Emanuele Zucca(Università della Svizzera italiana), Eva Kimby(Karolinska University Hospital), Felicitas Hitz(Kantonsspital St. Gallen), Thilo Zander(Luzerner Kantonsspital), Hanne Bersvendsen(University Hospital of North Norway), Simona Berardi Vilei(Swiss Group For Clinical Cancer Research), Peter de Nully Brown(Copenhagen University Hospital), Hans Hagberg(Uppsala University Hospital), Fatime Krasniqi(University Hospital of Basel), Hanne Hawle(Swiss Group For Clinical Cancer Research), Ulrich Mey(Kantonsspital Graubünden), Michele Ghielmini(Institute of Oncology Research), Stefanie Hayoz(Swiss Group For Clinical Cancer Research), Walter Mingrone(Kantonsschule Olten), Micaela Hernberg(Apple (Israel)), Björn E. Wahlin(Karolinska University Hospital), Urban Novak(University of Bern), Mario Bargetzi(Kantonsspital Aarau), Bjørn Østenstad(Oslo University Hospital), Andreas Lohri(Kantonsspital St. Gallen), Andrés J.M. Ferreri(Vita-Salute San Raffaele University), Stefan Dirnhofer(University of Basel), Stéphanie Rondeau(Kantonsspital St. Gallen), Anna Vanazzi(European Institute of Oncology), Ann‐Sofie Johansson(University Hospital of Umeå), Daniel Rauch(Washington University in St. Louis)
Cited by 61
Related Papers
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k
The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee
|Blood|2022|1.5k
High-dose cytarabine plus high-dose methotrexate versus high-dose methotrexate alone in patients with primary CNS lymphoma: a randomised phase 2 trial
|The Lancet|2009|665
Chronic lymphocytic leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
|Annals of Oncology|2020|568